3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Phase 1
1
Status
Terminated
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Other
1
Myeloid
1
Lymphoid
1
Conditions
Unspecified Adult Solid Tumor, Protocol Specific
1
Primary Myelofibrosis
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Myelodysplastic Syndromes
1
Mucositis
1
Lymphoma, Non-Hodgkin
1
Leukemia, Myeloid, Acute
1
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
1
Leukemia, Lymphocytic, Chronic, B-Cell
1
Hodgkin Disease
1
Interventions
Cyclophosphamide
24
fludarabine phosphate
22
Filgrastim
15
Gemcitabine
14
fludarabine
13
Rituximab
13
Brentuximab Vedotin
13
Peripheral Blood Stem Cell Transplantation
12
Whole-Body Irradiation
11
Vorinostat
11
Tacrolimus
11
Bortezomib
10
Mycophenolic Acid
9
Melphalan
9
Etoposide
9
Busulfan
9
Sirolimus
8
Lenalidomide
8
Azacitidine
8
Nivolumab
7
Dexamethasone
7
pembrolizumab
6
Radiotherapy
6
Cytarabine
6
Antilymphocyte Serum
6
romidepsin
5
aldesleukin
5
Panobinostat
5
Leucovorin
5
Doxorubicin
5
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 1
×
Hodgkin Disease
×
angiotensin I (1-7)
×
Clear all
NCT01300611
2020-12-08
USBTXA127CBT
Tarix Pharmaceuticals
Phase 1
Terminated
20 enrolled